{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:40:29Z","timestamp":1792629629992,"version":"4.5.0"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG 29289"],"award-info":[{"award-number":["IG 29289"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG 27531"],"award-info":[{"award-number":["IG 27531"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ctrv.2025.103038","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T01:00:05Z","timestamp":1760662805000},"page":"103038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Precision oncology in gastric cancer: Shaping the future of personalized treatment"],"prefix":"10.1016","volume":"141","author":[{"given":"Cristina","family":"Migliore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Fenocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5069-1503","authenticated-orcid":false,"given":"Simona","family":"Corso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.103038_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2025.103038_b0010","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/cncr.11568","article-title":"Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma","volume":"98","author":"Wu","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0015","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.gastro.2023.01.038","article-title":"Hereditary Diffuse Gastric Cancer","volume":"164","author":"Decourtye-Espiard","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2025.103038_b0020","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/S1470-2045(14)71016-2","article-title":"Familial gastric cancer: genetic susceptibility, pathology, and implications for management","volume":"16","author":"Oliveira","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0025","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103038_b0030","unstructured":"Lordick F, Candia Montero L, Castelo-Branco L, Pentheroudakis G, Sessa C, Smyth EC. ESMO Gastric Cancer Living Guideline v1.4. 2024."},{"key":"10.1016\/j.ctrv.2025.103038_b0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103038_b0040","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103038_b0045","unstructured":"FDA amends pembrolizumab's gastric cancer indication. 2023."},{"key":"10.1016\/j.ctrv.2025.103038_b0050","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0055","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2025.103038_b0065","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103038_b0070","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0075","article-title":"Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers during Prescreening for the phase III FORTITUDE-101 Trial","volume":"9","author":"Rha","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0080","unstructured":"AMGEN announces positive topline PHASE 3 results for bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) positive first-line gastric cancer. 2025."},{"key":"10.1016\/j.ctrv.2025.103038_b0085","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(25)00130-5","article-title":"TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial","volume":"26","author":"Zaanan","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0090","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1016\/S1470-2045(25)00416-4","article-title":"Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX - Authors' reply","volume":"26","author":"Zaanan","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0095","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0100","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S2468-1253(21)00313-7","article-title":"Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial","volume":"6","author":"Xu","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2025.103038_b0105","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0110","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial","volume":"14","author":"Lordick","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0120","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S1470-2045(14)70024-5","article-title":"Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial","volume":"15","author":"Dutton","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0125","unstructured":"Digestive System Tumours WHO Classification of Tumours, 5th Edition, Volume 12019."},{"key":"10.1016\/j.ctrv.2025.103038_b0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT a HISTO-CLINICAL CLASSIFICATION","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta Pathol Microbiol Scand"},{"key":"10.1016\/j.ctrv.2025.103038_b0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13304-018-0546-0","article-title":"Clinical impact of molecular classifications in gastric cancer","volume":"70","author":"Marrelli","year":"2018","journal-title":"Updates Surg"},{"key":"10.1016\/j.ctrv.2025.103038_b0140","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3389\/fonc.2020.01212","article-title":"Analysis of the Incidence and Survival of Gastric Cancer based on the Lauren Classification: a Large Population-based Study using SEER","volume":"10","author":"Tang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0145","doi-asserted-by":"crossref","first-page":"148","DOI":"10.21037\/jgo.2017.01.10","article-title":"Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis","volume":"8","author":"Petrelli","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0150","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.3748\/wjg.v20.i19.5679","article-title":"Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value","volume":"20","author":"Berlth","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2025.103038_b0155","article-title":"Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances","author":"Nakamura","year":"1968","journal-title":"Gan"},{"key":"10.1016\/j.ctrv.2025.103038_b0160","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/gut.33.5.606","article-title":"Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma","volume":"33","author":"Goseki","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2025.103038_b0165","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2025.103038_b0170","article-title":"Clinical significance of four Molecular Subtypes of Gastric Cancer Identified by the Cancer Genome Atlas Project","author":"Sohn","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0175","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13073-017-0484-3","article-title":"Actionable gene-based classification toward precision medicine in gastric cancer","volume":"9","author":"Ichikawa","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0180","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0185","doi-asserted-by":"crossref","first-page":"66305","DOI":"10.18632\/oncotarget.19985","article-title":"Development of mesenchymal subtype gene signature for clinical application in gastric cancer","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2025.103038_b0190","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.04.042","article-title":"Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy","volume":"141","author":"Tan","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2025.103038_b0195","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/j.gastro.2013.05.010","article-title":"Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil","volume":"145","author":"Lei","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2025.103038_b0200","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0205","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41467-018-03121-2","article-title":"A proteomic landscape of diffuse-type gastric cancer","volume":"9","author":"Ge","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.103038_b0210","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ccell.2018.12.003","article-title":"Proteogenomic Characterization of Human Early-Onset Gastric Cancer","volume":"35","author":"Mun","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2025.103038_b0215","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/2326-6066.CIR-18-0436","article-title":"Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures","volume":"7","author":"Zeng","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0220","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2014-308252","article-title":"Signatures of tumour immunity distinguish asian and non-asian gastric adenocarcinomas","volume":"64","author":"Lin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2025.103038_b0225","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.annonc.2020.04.011","article-title":"Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas","volume":"31","author":"Derks","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41698-022-00251-1","article-title":"Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity","volume":"6","author":"Kim","year":"2022","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0235","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","article-title":"Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-specific Expression Programs in Gastric Cancer","volume":"12","author":"Kumar","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2025.103038_b0240","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.7150\/thno.71833","article-title":"Single-cell landscape reveals active cell subtypes and their interaction in the tumor microenvironment of gastric cancer","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ctrv.2025.103038_b0245","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","article-title":"Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma","volume":"8","author":"Pectasides","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2025.103038_b0255","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/modpathol.2012.205","article-title":"Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas","volume":"26","author":"Cho","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2025.103038_b0260","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12876-015-0231-4","article-title":"Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer","volume":"15","author":"Stahl","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ctrv.2025.103038_b0265","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-15-1246","article-title":"High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial","volume":"6","author":"Pearson","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2025.103038_b0270","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/gutjnl-2019-320368","article-title":"Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2025.103038_b0275","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-24-0605","article-title":"Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution","author":"Ma","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2025.103038_b0280","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2025.103038_b0285","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ijc.31304","article-title":"Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor","volume":"143","author":"Kim","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0290","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41416-018-0008-y","article-title":"Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models","volume":"118","author":"Shimada","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0295","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1475-2867-14-10","article-title":"Correlation between HER-2\/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines","volume":"14","author":"Cui","year":"2014","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ctrv.2025.103038_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a Cancer Dependency Map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2025.103038_b0305","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0310","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s12935-020-01536-w","article-title":"Establishment and characterization of a new gastric cancer cell line, XGC-1","volume":"20","author":"Peng","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ctrv.2025.103038_b0315","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cancergencyto.2009.04.020","article-title":"Establishment and conventional cytogenetic characterization of three gastric cancer cell lines","volume":"195","author":"Leal","year":"2009","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.ctrv.2025.103038_b0320","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF02899281","article-title":"Characterization of four new gastric cancer cell lines","volume":"63","author":"Vollmers","year":"1993","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"10.1016\/j.ctrv.2025.103038_b0325","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1002\/cam4.5403","article-title":"Establishment of a gastric cancer cell line with high microsatellite instability, OCUM-13, derived from Borrmann type-2 primary tumor","volume":"12","author":"Yamamoto","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060585","article-title":"Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts","volume":"8","author":"Kuwata","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ctrv.2025.103038_b0335","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1590\/S0100-879X2004001200008","article-title":"Conventional cytogenetic characterization of a new cell line, ACP01, established from a primary human gastric tumor","volume":"37","author":"Lima","year":"2004","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0340","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1158\/0008-5472.CAN-19-1166","article-title":"A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits","volume":"79","author":"Corso","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0345","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00193936","article-title":"Establishment and characterization of two cell lines derived from human diffuse gastric carcinomas xenografted in nude mice","volume":"428","author":"Gartner","year":"1996","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2025.103038_b0350","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.stem.2009.11.013","article-title":"Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro","volume":"6","author":"Barker","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ctrv.2025.103038_b0355","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/j.gastro.2014.09.042","article-title":"In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection","volume":"148","author":"Bartfeld","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2025.103038_b0360","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1038\/nprot.2013.153","article-title":"In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture","volume":"8","author":"Miyoshi","year":"2013","journal-title":"Nat Protoc"},{"key":"10.1016\/j.ctrv.2025.103038_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.09.016","article-title":"A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening","volume":"23","author":"Yan","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ctrv.2025.103038_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.07.027","article-title":"Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis","volume":"174","author":"Nanki","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2025.103038_b0375","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/gutjnl-2017-314549","article-title":"Human gastric cancer modelling using organoids","volume":"68","author":"Seidlitz","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.ctrv.2025.103038_b0380","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-023-01919-3","article-title":"Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold","volume":"23","author":"Schmache","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0385","article-title":"Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0390","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3390\/organoids3040016","article-title":"Precision Medicine for Gastric Cancer: Current State of Organoid Drug Testing","volume":"3","author":"Silva","year":"2024","journal-title":"Organoids"},{"key":"10.1016\/j.ctrv.2025.103038_b0395","article-title":"A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology","volume":"18","author":"Xu","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.103038_b0400","article-title":"High-Throughput Chemotherapeutic Drug Screening System for Gastric Cancer (Cure-GA)","author":"Lee","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2024.130566","article-title":"Gastric cancer patient-derived organoids model for the therapeutic drug screening","volume":"1868","author":"Xu","year":"2024","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.ctrv.2025.103038_b0410","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41420-021-00803-7","article-title":"Establishment of gastric signet ring cell carcinoma organoid for the therapeutic drug testing","volume":"8","author":"Li","year":"2022","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.ctrv.2025.103038_b0415","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-4939-3603-8_4","article-title":"An Air-Liquid Interface Culture System for 3D Organoid Culture of Diverse Primary Gastrointestinal Tissues","volume":"1422","author":"Li","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ctrv.2025.103038_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid Modeling of the Tumor Immune Microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2025.103038_b0425","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1038\/s41467-021-25122-4","article-title":"Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts","volume":"12","author":"Na","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.103038_bib856","doi-asserted-by":"crossref","first-page":"22172","DOI":"10.1038\/srep22172","article-title":"Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer","volume":"6","author":"Choi","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2025.103038_bib857","doi-asserted-by":"crossref","unstructured":"Yu X, Chen Y, Lu J, He K, Chen Y, Ding Y, Jin K, Wang H, Zhang H, Wang H, Teng L. Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study. Front Oncol. 2022 Nov 18;12:985154.","DOI":"10.3389\/fonc.2022.985154"},{"key":"10.1016\/j.ctrv.2025.103038_b0430","first-page":"553","article-title":"Modeling human gastric cancers in immunocompetent mice","volume":"21","author":"Zhang","year":"2024","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0435","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2019.09.026","article-title":"Mouse Models of Human Gastric Cancer Subtypes with Stomach-specific CreERT2-Mediated Pathway Alterations","volume":"157","author":"Seidlitz","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2025.103038_b0440","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s43018-023-00686-w","article-title":"Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease","volume":"5","author":"Leibold","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0445","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in Combination with Capecitabine Plus Oxaliplatin in Human Epidermal Growth factor Receptor 2-positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013\/LOGiC\u2013A Randomized phase III Trial","volume":"34","author":"Hecht","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0450","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in asian populations: TyTAN\u2013a randomized, phase III study","volume":"32","author":"Satoh","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0455","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/2159-8290.CD-18-0598","article-title":"EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer","volume":"9","author":"Sanchez-Vega","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2025.103038_b0460","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1007\/s10120-019-00958-4","article-title":"A phase I\/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer","volume":"22","author":"Kim","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0465","doi-asserted-by":"crossref","first-page":"S857","DOI":"10.1016\/j.annonc.2023.09.1436","article-title":"1523P phase II dose optimization results from MOUNTAINEER-02: a study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)","volume":"34","author":"Tehfe","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0470","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in previously Treated HER2-positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0475","doi-asserted-by":"crossref","first-page":"S878","DOI":"10.1016\/j.annonc.2024.08.1467","article-title":"401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced\/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)","author":"Janjigian","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0480","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.22.00575","article-title":"Trastuzumab Deruxtecan in Anti-Human Epidermal Growth factor Receptor 2 Treatment-Naive patients with Human Epidermal Growth factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort results in a phase II Trial","volume":"41","author":"Yamaguchi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0485","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0490","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.23.02044","article-title":"Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: a Global phase I Trial","volume":"42","author":"Yao","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0495","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv"},{"key":"10.1016\/j.ctrv.2025.103038_b0500","doi-asserted-by":"crossref","first-page":"S749","DOI":"10.1016\/j.annonc.2022.07.589","article-title":"460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers","volume":"33","author":"Jhaveri","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0505","doi-asserted-by":"crossref","first-page":"S365","DOI":"10.1016\/j.annonc.2023.09.614","article-title":"438P phase I study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors","volume":"34","author":"Lin","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0555","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.10.004","article-title":"KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer","volume":"178","author":"Xu","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0570","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-024-02132-2","article-title":"Targeting HER2 in Gastroesophageal Cancer: a New Appetite for an Old Plight","author":"Cammarota","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2025.103038_b0575","doi-asserted-by":"crossref","unstructured":"Back J, Wermke M, Macoin J, Croset A, Kauh JS, Reddy V. GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers. Journal of Clinical Oncology.36:12053.","DOI":"10.1200\/JCO.2018.36.15_suppl.12053"},{"key":"10.1016\/j.ctrv.2025.103038_b0580","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-18-3654","article-title":"Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB\/HER2 Bispecific Antibody-Anticalin Fusion PRS-343","volume":"25","author":"Hinner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0585","doi-asserted-by":"crossref","first-page":"S607","DOI":"10.1016\/j.annonc.2021.08.1066","article-title":"544P a novel HER2\/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation","volume":"32","author":"Lee","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101068","article-title":"Development and evaluation of a human CD47\/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy","volume":"74","author":"Zhang","year":"2024","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ctrv.2025.103038_b0595","article-title":"Anti-PD-1\/Her2 Bispecific Antibody IBI315 Enhances the Treatment effect of Her2-positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis","volume":"10","author":"Lin","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.ctrv.2025.103038_b0600","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT204","article-title":"Abstract CT204: phase 1a\/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC)","volume":"85","author":"Modi","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0605","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2023.41.16_suppl.2538","article-title":"A phase 1\/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0610","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2020.38.15_suppl.3110","article-title":"SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist","volume":"38","author":"Metz","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2025.103038_b0510","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","article-title":"Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study","volume":"19","author":"Tabernero","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0515","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/1078-0432.CCR-22-2533","article-title":"HER2 Copy Number and Resistance Mechanisms in patients with HER2-positive Advanced Gastric Cancer Receiving initial Trastuzumab-based Therapy in JACOB Trial","volume":"29","author":"Pietrantonio","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0520","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-17-2781","article-title":"Biomarkers of Primary Resistance to Trastuzumab in HER2-positive Metastatic Gastric Cancer patients: the AMNESIA Case-Control Study","volume":"24","author":"Pietrantonio","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0525","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12103391","article-title":"History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer","volume":"12","author":"Ariga","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0530","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s10120-021-01165-w","article-title":"Personalized therapeutic strategies in HER2-driven gastric cancer","volume":"24","author":"Ughetto","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0535","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40364-022-00416-x","article-title":"HER2-targeted advanced metastatic gastric\/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives","volume":"10","author":"Li","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0540","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1200\/JCO.2025.43.16_suppl.4013","article-title":"Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial","volume":"43","author":"Elimova","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0545","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S1470-2045(25)00287-6","article-title":"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study","volume":"26","author":"Elimova","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0550","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12885-025-13749-1","article-title":"Exploring Zanidatamab's efficacy across HER2-positive Malignancies: a narrative review","volume":"25","author":"Kanwal","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0565","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/d41573-022-00040-2","article-title":"Bispecific antibodies in oncology","volume":"21","author":"Esfandiari","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2025.103038_b0615","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1016\/j.ymthe.2024.06.023","article-title":"Preclinical efficacy of a HER2 synNotch\/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification","volume":"32","author":"Cortese","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2025.103038_b0620","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.103038_b0625","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-24-0742","article-title":"Phase II Trial of HER-Vaxx, a B-cell Peptide-based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer patients under Platinum-based Chemotherapy (HERIZON)","volume":"30","author":"Tobias","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0630","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-up of the phase III CheckMate 649 Trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0635","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1186\/s12885-020-07251-z","article-title":"Safety and efficacy of sintilimab combined with oxaliplatin\/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial","volume":"20","author":"Jiang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0640","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/jama.2024.28463","article-title":"First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: the GEMSTONE-303 Randomized Clinical Trial","volume":"333","author":"Zhang","year":"2025","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2025.103038_b0645","article-title":"Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies","volume":"1880","author":"Song","year":"2025","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ctrv.2025.103038_b0650","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.apsb.2023.12.010","article-title":"Small-molecule agents for cancer immunotherapy","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ctrv.2025.103038_b0655","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0660","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0665","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim results from the Randomized, Multicenter, phase II\/III DANTE\/IKF-s633 Trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0670","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair\/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: the GERCOR NEONIPIGA phase II Study","volume":"41","author":"Andre","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0675","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0680","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib Plus Nivolumab in patients with Advanced Gastric or Colorectal Cancer: an Open-Label, Dose-Escalation, and Dose-expansion phase Ib Trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0685","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1200\/JCO.2021.39.3_suppl.230","article-title":"LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors\u2014Results from the gastric cancer cohort","volume":"39","author":"Chung","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2025.103038_b0690","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.gastro.2007.05.008","article-title":"Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies","volume":"133","author":"Wilson","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2025.103038_b0695","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007699","article-title":"Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors","volume":"11","author":"Magahis","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0700","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103038_b0705","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, Double-blind, Placebo-Controlled phase III Trial of Apatinib in patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0710","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-075696","article-title":"Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol","volume":"14","author":"Wu","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.ctrv.2025.103038_b0715","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/s41591-024-02989-6","article-title":"Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0720","article-title":"Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer","volume":"13","author":"Xu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0725","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO-25-00748","article-title":"Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: the phase III, Randomized LEAP-015 Study","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0730","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/annonc\/mdx107","article-title":"A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification","volume":"28","author":"Van Cutsem","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0735","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0740","doi-asserted-by":"crossref","first-page":"TPS4165","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4165","article-title":"Trial in progress: Phase 1b\/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus mFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102)","volume":"40","author":"Wainberg","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ctrv.2025.103038_b0745","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0750","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0755","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1158\/1078-0432.CCR-20-0121","article-title":"Optimized EGFR Blockade strategies in EGFR Addicted Gastroesophageal Adenocarcinomas","volume":"27","author":"Corso","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0760","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2016.70.3934","article-title":"Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer","volume":"35","author":"Petty","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0765","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1200\/JCO.21.02453","article-title":"Epidermal Growth factor Receptor Inhibition in Epidermal Growth factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience","volume":"40","author":"Maron","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0770","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1158\/0008-5472.CAN-25-0073","article-title":"AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer","volume":"85","author":"Conticelli","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0775","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.553876","article-title":"Targeting EGFR in Esophagogastric Cancer","volume":"10","author":"Maron","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0780","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0785","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1158\/0008-5472.CAN-22-2620","article-title":"BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors","volume":"83","author":"Petrelli","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0790","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215114","article-title":"Advancements and Obstacles of PARP Inhibitors in Gastric Cancer","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2025.103038_b0795","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00456","article-title":"Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in patients with Cancer with or without Mutations in Homologous Recombination Repair Genes","author":"Yap","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2014.04.003","article-title":"VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2","volume":"16","author":"Lim","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.ctrv.2025.103038_b0805","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2025.103038_b0810","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jcp.2008.060590","article-title":"TROP2 expression as prognostic marker for gastric carcinoma","volume":"62","author":"Muhlmann","year":"2009","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2025.103038_b0815","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.18632\/oncotarget.6733","article-title":"Trop2 is overexpressed in gastric cancer and predicts poor prognosis","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2025.103038_b0820","article-title":"Targeting Trop-2 in cancer: recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ctrv.2025.103038_b0825","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT038","article-title":"Abstract CT038: Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a phase 2 study","volume":"84","author":"Rodon","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0830","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103038_b0835","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0840","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","article-title":"ILUSTRO: phase II Multicohort Trial of Zolbetuximab in patients with Advanced or Metastatic Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma","volume":"29","author":"Klempner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0845","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","article-title":"The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial","volume":"31","author":"Ruan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103038_b0850","first-page":"78","article-title":"Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: a retrospective study. Chin","volume":"36","author":"Qi","year":"2024","journal-title":"J Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103038_b0855","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:52:03Z","timestamp":1764143523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":173,"alternative-id":["S0305737225001604"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103038","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision oncology in gastric cancer: Shaping the future of personalized treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103038"}}